Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity
We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD). A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platele...
Saved in:
Published in | Thrombosis research Vol. 131; no. 6; pp. 508 - 513 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Ltd
01.06.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD).
A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR.
All subjects were dichotomized according to PRI medians (normal-responders: PRI<56.5%, n=17 and low-responders: PRI>56.5%, n=16) and PAG medians (normal-responders: PAG<43%, n=17 and low-responders: PAG>43%, n=16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders (P=0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r=−0.403, P=0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity (CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P=0.028).
The present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population. |
---|---|
AbstractList | We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD).OBJECTIVESWe aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD).A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300 mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR.MATERIALS AND METHODSA total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300 mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR.All subjects were dichotomized according to PRI medians (normal-responders: PRI < 56.5%, n = 17 and low-responders: PRI > 56.5%, n = 16) and PAG medians (normal-responders: PAG < 43%, n = 17 and low-responders: PAG > 43%, n = 16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders (P = 0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r = -0.403, P = 0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity (CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P = 0.028).RESULTSAll subjects were dichotomized according to PRI medians (normal-responders: PRI < 56.5%, n = 17 and low-responders: PRI > 56.5%, n = 16) and PAG medians (normal-responders: PAG < 43%, n = 17 and low-responders: PAG > 43%, n = 16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders (P = 0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r = -0.403, P = 0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity (CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P = 0.028).The present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population.CONCLUSIONSThe present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population. Abstract Objectives We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD). Materials and Methods A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300 mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR. Results All subjects were dichotomized according to PRI medians (normal-responders: PRI < 56.5%, n = 17 and low-responders: PRI > 56.5%, n = 16) and PAG medians (normal-responders: PAG < 43%, n = 17 and low-responders: PAG > 43%, n = 16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders ( P = 0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r = − 0.403, P = 0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity ( CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P = 0.028). Conclusions The present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population. We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD). A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300 mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR. All subjects were dichotomized according to PRI medians (normal-responders: PRI < 56.5%, n = 17 and low-responders: PRI > 56.5%, n = 16) and PAG medians (normal-responders: PAG < 43%, n = 17 and low-responders: PAG > 43%, n = 16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders (P = 0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r = -0.403, P = 0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity (CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P = 0.028). The present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population. We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD). A total of 33 consecutive non-diabetic CHD patients scheduled for percutaneous coronary intervention were enrolled. Platelet reactivity after clopidogrel loading dose (300mg) was determined by two methods [platelet reactivity index (PRI), measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry and ADP-induced platelet aggregation (PAG), measured by light transmission aggregometry]. Total platelet RNA was isolated from purified platelets (CD45 magnetic bead negative selection) to quantify miR-223 and miR-96 expression by real-time PCR. All subjects were dichotomized according to PRI medians (normal-responders: PRI<56.5%, n=17 and low-responders: PRI>56.5%, n=16) and PAG medians (normal-responders: PAG<43%, n=17 and low-responders: PAG>43%, n=16). Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders (P=0.037). No differential expression of miR-223 and miR-96 was observed via PAG determination between normal- and low-responders. In addition, miR-223 expression, but not miR96, was statistically correlated with PRI (Spearman r=−0.403, P=0.020). Stepwise binary logistic regression analysis revealed that among factors that potentially influence platelet reactivity (CYP2C19*2 loss-of-function genotypes, use of calcium channel blockers/proton-pump inhibitors, age, obesity, smoking and platelet microRNAs), decreased miR-223 expression was the only independent predictor associated with the presence of PRI-determined low responders to clopidogrel (OR 0.189, 95% CI 0.043 to 0.836, P=0.028). The present work identifies decreased platelet miR-223 expression as a novel mechanism involved in blunted platelet response to clopidogrel in a Chinese population. |
Author | Liu, Xing Zhao, Ji-Hong Zhang, Wen-Cheng Jiang, Tie-Min Ge, Lan Li, Yu-Ming Ji, Wen-Jie Lu, Rui-Yi Zhou, Xin Shi, Rui Zeng, Shan Zhang, Ying-Ying |
Author_xml | – sequence: 1 givenname: Rui surname: Shi fullname: Shi, Rui organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China – sequence: 2 givenname: Lan surname: Ge fullname: Ge, Lan organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China – sequence: 3 givenname: Xin surname: Zhou fullname: Zhou, Xin organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China – sequence: 4 givenname: Wen-Jie surname: Ji fullname: Ji, Wen-Jie organization: Departments of Respiratory and Critical Care Medicine, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China – sequence: 5 givenname: Rui-Yi surname: Lu fullname: Lu, Rui-Yi organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China – sequence: 6 givenname: Ying-Ying surname: Zhang fullname: Zhang, Ying-Ying organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China – sequence: 7 givenname: Shan surname: Zeng fullname: Zeng, Shan organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China – sequence: 8 givenname: Xing surname: Liu fullname: Liu, Xing organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China – sequence: 9 givenname: Ji-Hong surname: Zhao fullname: Zhao, Ji-Hong organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China – sequence: 10 givenname: Wen-Cheng surname: Zhang fullname: Zhang, Wen-Cheng organization: Department of Physiology and Pathophysiology, Logistics University of the Chinese People’s Armed Police Forces, China – sequence: 11 givenname: Tie-Min surname: Jiang fullname: Jiang, Tie-Min organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China – sequence: 12 givenname: Yu-Ming surname: Li fullname: Li, Yu-Ming email: cardiolab@gmail.com organization: Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital, Logistics University of the Chinese People’s Armed Police Forces, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23498169$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkt1rFDEUxYNU7Lb6L5R59GXG3GQ-QURp_SgUhKrPMXvnTjdrZjIm2er-92bZLoU-2D4Fwjm_5J5zT9jR5CZi7Ax4ARzqN-sirrwbPYVCcJAFFwWH6hlbQNt0uSgbccQWnJddLtuyPWYnIaw5hwa66gU7FrLsWqi7Bft5QehJB-qz2epIlmI2mutcCJnR3znxg3FTZkKmQ3BokqTP_pi4ylbmZpW5KUfrZtO7G0_2HpGQGM2tiduX7PmgbaBXd-cp-_Hp4_fzL_nV18-X5x-uciybNuadTD_rK75sKgFSUA_lICTnmEYYqkYgNumq1kDLqiZYAi913XMskWMn5CBP2es9d_bu94ZCVKMJSNbqidwmKJB13aapAJL07E66WY7Uq9mbUfutOqSSBG_3AvQuBE-DQhN1TEFEr41VwNWuBLVWhxLUrgTFhUolJHv9wH544VHj-72RUlC3hrwKaGhC6o0njKp35nHEuwcItGYyqO0v2lJYu42fUg0KVEgG9W23IrsNgZQ1bwX_P-ApP_gHit7P1Q |
CitedBy_id | crossref_primary_10_3389_fendo_2018_00002 crossref_primary_10_1007_s10557_022_07370_8 crossref_primary_10_1080_09537104_2022_2042236 crossref_primary_10_1093_eurheartj_ehy234 crossref_primary_10_1016_j_lfs_2015_04_016 crossref_primary_10_1155_2014_450814 crossref_primary_10_1155_2023_9322188 crossref_primary_10_3390_cells10123526 crossref_primary_10_3390_jcm11071763 crossref_primary_10_3390_jcm11226849 crossref_primary_10_1016_j_ijcard_2024_132073 crossref_primary_10_1161_JAHA_121_021129 crossref_primary_10_1177_03000605211016209 crossref_primary_10_1016_j_tcm_2019_08_005 crossref_primary_10_1161_CIRCRESAHA_117_305784 crossref_primary_10_3389_fphys_2021_658524 crossref_primary_10_1161_CIRCRESAHA_116_309303 crossref_primary_10_1161_CIRCRESAHA_114_305663 crossref_primary_10_1177_1076029617726600 crossref_primary_10_1155_2015_981841 crossref_primary_10_1111_ijlh_13261 crossref_primary_10_1055_s_0042_1760258 crossref_primary_10_1155_2015_682857 crossref_primary_10_3390_jpm11060508 crossref_primary_10_1055_s_0040_1718730 crossref_primary_10_15690_vramn1214 crossref_primary_10_3389_fphar_2022_811422 crossref_primary_10_1007_s11239_017_1537_6 crossref_primary_10_1111_eci_13149 crossref_primary_10_1080_15476286_2021_1885188 crossref_primary_10_3390_ijms21103477 crossref_primary_10_3390_ijms21176150 crossref_primary_10_1089_ars_2020_8139 crossref_primary_10_26442_00403660_2019_08_000389 crossref_primary_10_1007_s11239_013_1022_9 crossref_primary_10_1016_j_thromres_2017_07_011 crossref_primary_10_1080_09537104_2022_2042233 crossref_primary_10_1055_s_0041_1730375 crossref_primary_10_3390_ijerph14030301 crossref_primary_10_3390_ijms21082897 crossref_primary_10_2217_pgs_2019_0089 crossref_primary_10_1089_ars_2017_7289 crossref_primary_10_3390_genes16030312 crossref_primary_10_1038_s41598_020_63263_6 crossref_primary_10_1080_09537104_2019_1636019 crossref_primary_10_1055_s_0040_1718400 crossref_primary_10_3390_cells11040607 crossref_primary_10_1038_s41598_023_42868_7 crossref_primary_10_1038_s41598_017_01887_x crossref_primary_10_3390_medicina61010162 crossref_primary_10_1160_TH13_11_0977 crossref_primary_10_3390_biology11050644 crossref_primary_10_1160_TH14_07_0622 crossref_primary_10_1161_CIRCRESAHA_117_306817 crossref_primary_10_1093_cvr_cvae138 crossref_primary_10_1111_jth_12788 crossref_primary_10_1186_s12933_022_01517_5 crossref_primary_10_1016_j_thromres_2018_03_021 crossref_primary_10_3389_fendo_2018_00074 crossref_primary_10_1002_prp2_751 crossref_primary_10_1007_s10557_019_06855_3 crossref_primary_10_1111_jth_14442 crossref_primary_10_3109_09537104_2014_974527 crossref_primary_10_1080_09537104_2023_2200860 crossref_primary_10_1097_MPH_0000000000002127 crossref_primary_10_3390_ijms232415645 crossref_primary_10_1080_09537104_2018_1475635 crossref_primary_10_1016_j_lfs_2020_117364 crossref_primary_10_3390_ijms23063301 crossref_primary_10_1016_j_thromres_2013_06_002 crossref_primary_10_1371_journal_pone_0122784 crossref_primary_10_3389_fcvm_2020_610561 crossref_primary_10_1055_a_1478_2105 crossref_primary_10_3390_ijms22094799 crossref_primary_10_1158_1535_7163_MCT_21_0050 crossref_primary_10_1016_j_thromres_2013_03_017 crossref_primary_10_3390_jcm11061484 crossref_primary_10_1155_2017_4080364 crossref_primary_10_1007_s10557_021_07229_4 crossref_primary_10_3389_fphys_2021_652579 |
Cites_doi | 10.1146/annurev.cellbio.19.110701.155609 10.1038/nsmb.1651 10.1182/blood-2010-09-299719 10.1182/blood-2011-03-291971 10.1161/CIRCULATIONAHA.109.866533 10.1016/j.jcin.2010.12.009 10.1080/09537100802272634 10.1111/j.1538-7836.2011.04414.x 10.1161/CIRCULATIONAHA.106.682658 10.1093/eurheartj/ehr407 10.1111/j.1538-7836.2007.02656.x 10.1016/j.cell.2009.01.002 10.1111/j.1538-7836.2009.03700.x 10.1136/hrt.2011.227272 10.1111/j.1538-7836.2007.02609.x 10.1093/eurheartj/ehr236 10.1016/j.jacc.2012.03.056 10.1136/hrt.2010.220491 10.1146/annurev-biochem-060308-103103 10.1161/CIRCINTERVENTIONS.111.962555 10.1111/j.1538-7836.2005.01751.x 10.1016/j.ahj.2010.06.004 10.1016/j.jacc.2008.07.055 10.1038/nature09267 10.1111/j.1538-7836.2004.01063.x 10.1160/TH07-05-0324 10.1016/S0092-8674(04)00045-5 10.1111/j.1423-0410.2010.01333.x 10.1016/j.jacc.2008.05.054 10.1056/NEJMoa0809171 10.4244/51 10.1001/jama.2009.1232 10.1016/j.jacc.2012.06.004 |
ContentType | Journal Article |
Copyright | 2013 Elsevier Ltd Elsevier Ltd Copyright © 2013 Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: 2013 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2013 Elsevier Ltd. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.thromres.2013.02.015 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-2472 |
EndPage | 513 |
ExternalDocumentID | 23498169 10_1016_j_thromres_2013_02_015 S0049384813000820 1_s2_0_S0049384813000820 |
Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K WUQ X7M Z5R ZGI ~G- 0SF AACTN AFCTW AFKWA AJOXV AMFUW NCXOZ RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c478t-93195d50b752132ed14f2300c049f572cc7d146a1eb56e1b104a6d0c4c0c923f3 |
IEDL.DBID | .~1 |
ISSN | 0049-3848 1879-2472 |
IngestDate | Mon Jul 21 09:22:38 EDT 2025 Thu Apr 03 07:00:51 EDT 2025 Tue Jul 01 02:27:34 EDT 2025 Thu Apr 24 23:08:30 EDT 2025 Fri Feb 23 02:31:40 EST 2024 Sun Feb 23 10:19:19 EST 2025 Tue Aug 26 16:32:37 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | miRNAs PRI LVEF PPI cGMP cAMP UA ADP Cr MFI RBC DBP ACEI real time PCR WBC BMI SBP VASP CCB NSTE-ACS PGE1 Ago 3’UTR Platelet function test TB Vasodilator-stimulated phosphoprotein TC ARB TG High on-treatment platelet reactivity MiroRNAs PAG PCI LDPs Clopidogrel CHD microRNAs red blood cells vasodilator-stimulated phosphoprotein systolic blood pressure total cholesterol left ventricular ejection fraction percutaneous coronary intervention diastolic blood pressure prostaglandin E1 white blood cells adenosine diphosphate uric acid argonaute mean fluorescence intensity body mass index angiotensin-converting enzyme inhibitor 3’untranslated region cyclic guanosine monophosphate total bilirubin leukocyte-depleted platelets platelet aggregation proton pump inhibitors platelet reactivity index creatinine angiotensin receptor blockers calcium channel blockers triglycerides cyclic adenosine monophosphate real time polymerase chain reaction coronary heart disease non-ST-segment elevation acute coronary syndrome |
Language | English |
License | Copyright © 2013 Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c478t-93195d50b752132ed14f2300c049f572cc7d146a1eb56e1b104a6d0c4c0c923f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
PMID | 23498169 |
PQID | 1366822311 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_1366822311 pubmed_primary_23498169 crossref_citationtrail_10_1016_j_thromres_2013_02_015 crossref_primary_10_1016_j_thromres_2013_02_015 elsevier_sciencedirect_doi_10_1016_j_thromres_2013_02_015 elsevier_clinicalkeyesjournals_1_s2_0_S0049384813000820 elsevier_clinicalkey_doi_10_1016_j_thromres_2013_02_015 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-06-01 |
PublicationDateYYYYMMDD | 2013-06-01 |
PublicationDate_xml | – month: 06 year: 2013 text: 2013-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Thrombosis research |
PublicationTitleAlternate | Thromb Res |
PublicationYear | 2013 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Aleil, Ravanat, Cazenave, Rochoux, Heitz, Gachet (bb0070) 2005; 3 O'Connell, Zhao, Rao (bb0175) 2011; 118 Varenhorst, James, Erlinge, Braun, Brandt, Winters (bb0065) 2009; 157 Ungar, Hughson (bb0155) 2003; 19 Landry, Plante, Ouellet, Perron, Rousseau, Provost (bb0100) 2009; 16 Nagalla, Shaw, Kong, Kondkar, Edelstein, Ma (bb0125) 2011; 117 Tantry, Kereiakes, Gurbel (bb0035) 2011; 4 Kondkar, Bray, Leal, Nagalla, Liu, Jin (bb0105) 2010; 8 Hamm, Bassand, Agewall, Bax, Boersma, Bueno (bb0110) 2011; 32 LaValley (bb0135) 2008; 117 Bonello, Paganelli, Arpin-Bornet, Auquier, Sampol, Dignat-George (bb0055) 2007; 5 Blindt, Stellbrink, de Taeye, Muller, Kiefer, Yagmur (bb0075) 2007; 98 Sianos, Morel, Kappetein, Morice, Colombo, Dawkins (bb0130) 2005; 1 Oh, Park, Kang, Park, Na, Kang (bb0160) 2012; 98 Breet, van Werkum, Bouman, Kelder, Harmsze, Hackeng (bb0015) 2011; 97 Paniccia, Antonucci, Gori, Marcucci, Giglioli, Antoniucci (bb0150) 2007; 5 Schubert, Devine (bb0140) 2010; 99 Aradi, Komocsi, Vorobcsuk, Rideg, Tokes-Fuzesi, Magyarlaki (bb0010) 2010; 160 Silvain, Cayla, Hulot, Finzi, Kerneis, O'Connor (bb0050) 2012; 33 Guo, Ingolia, Weissman, Bartel (bb0085) 2010; 466 Bartel (bb0080) 2004; 116 Jneid, Anderson, Wright, Adams, Bridges, Casey (bb0005) 2012; 60 Zampetaki, Willeit, Tilling, Drozdov, Prokopi, Renard (bb0170) 2012; 60 Shuldiner, O'Connell, Bliden, Gandhi, Ryan, Horenstein (bb0025) 2009; 302 Siller-Matula, Panzer, Jilma (bb0060) 2008; 19 Mega, Close, Wiviott, Shen, Hockett, Brandt (bb0020) 2009; 360 Berger, Bhatt, Steinhubl, Shao, Steg, Montalescot (bb0040) 2009; 120 Fabian, Sonenberg, Filipowicz (bb0090) 2010; 79 Cuisset, Frere, Quilici, Barbou, Morange, Hovasse (bb0115) 2006; 4 Siller-Matula, Lang, Christ, Jilma (bb0030) 2008; 52 Cuisset, Cayla, Frere, Quilici, Poyet, Gaborit (bb0120) 2009; 5 Jeong, Tantry, Kim, Koh, Kwon, Park (bb0165) 2011; 4 Ang, Palakodeti, Khalid, Tsimikas, Idrees, Tran (bb0045) 2008; 52 Bartel (bb0095) 2009; 136 Fernando, Bassler, Habersberger, Sheffield, Sharma, Dart (bb0145) 2011; 9 Aleil (10.1016/j.thromres.2013.02.015_bb0070) 2005; 3 Sianos (10.1016/j.thromres.2013.02.015_bb0130) 2005; 1 Ang (10.1016/j.thromres.2013.02.015_bb0045) 2008; 52 Hamm (10.1016/j.thromres.2013.02.015_bb0110) 2011; 32 O'Connell (10.1016/j.thromres.2013.02.015_bb0175) 2011; 118 Ungar (10.1016/j.thromres.2013.02.015_bb0155) 2003; 19 Varenhorst (10.1016/j.thromres.2013.02.015_bb0065) 2009; 157 Landry (10.1016/j.thromres.2013.02.015_bb0100) 2009; 16 Paniccia (10.1016/j.thromres.2013.02.015_bb0150) 2007; 5 LaValley (10.1016/j.thromres.2013.02.015_bb0135) 2008; 117 Jeong (10.1016/j.thromres.2013.02.015_bb0165) 2011; 4 Fernando (10.1016/j.thromres.2013.02.015_bb0145) 2011; 9 Siller-Matula (10.1016/j.thromres.2013.02.015_bb0060) 2008; 19 Zampetaki (10.1016/j.thromres.2013.02.015_bb0170) 2012; 60 Shuldiner (10.1016/j.thromres.2013.02.015_bb0025) 2009; 302 Siller-Matula (10.1016/j.thromres.2013.02.015_bb0030) 2008; 52 Aradi (10.1016/j.thromres.2013.02.015_bb0010) 2010; 160 Mega (10.1016/j.thromres.2013.02.015_bb0020) 2009; 360 Nagalla (10.1016/j.thromres.2013.02.015_bb0125) 2011; 117 Guo (10.1016/j.thromres.2013.02.015_bb0085) 2010; 466 Breet (10.1016/j.thromres.2013.02.015_bb0015) 2011; 97 Kondkar (10.1016/j.thromres.2013.02.015_bb0105) 2010; 8 Cuisset (10.1016/j.thromres.2013.02.015_bb0115) 2006; 4 Blindt (10.1016/j.thromres.2013.02.015_bb0075) 2007; 98 Schubert (10.1016/j.thromres.2013.02.015_bb0140) 2010; 99 Cuisset (10.1016/j.thromres.2013.02.015_bb0120) 2009; 5 Berger (10.1016/j.thromres.2013.02.015_bb0040) 2009; 120 Fabian (10.1016/j.thromres.2013.02.015_bb0090) 2010; 79 Silvain (10.1016/j.thromres.2013.02.015_bb0050) 2012; 33 Jneid (10.1016/j.thromres.2013.02.015_bb0005) 2012; 60 Tantry (10.1016/j.thromres.2013.02.015_bb0035) 2011; 4 Bartel (10.1016/j.thromres.2013.02.015_bb0080) 2004; 116 Bartel (10.1016/j.thromres.2013.02.015_bb0095) 2009; 136 Bonello (10.1016/j.thromres.2013.02.015_bb0055) 2007; 5 Oh (10.1016/j.thromres.2013.02.015_bb0160) 2012; 98 23597855 - Thromb Res. 2013 Jun;131(6):472-3 |
References_xml | – volume: 32 start-page: 2999 year: 2011 end-page: 3054 ident: bb0110 article-title: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) publication-title: Eur Heart J – volume: 19 start-page: 493 year: 2003 end-page: 517 ident: bb0155 article-title: SNARE protein structure and function publication-title: Annu Rev Cell Dev Biol – volume: 157 start-page: e561 year: 2009 end-page: e569 ident: bb0065 article-title: Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin publication-title: Am Heart J – volume: 98 start-page: 1329 year: 2007 end-page: 1334 ident: bb0075 article-title: The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis publication-title: Thromb Haemost – volume: 52 start-page: 1052 year: 2008 end-page: 1059 ident: bb0045 article-title: Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel publication-title: J Am Coll Cardiol – volume: 4 start-page: 542 year: 2006 end-page: 549 ident: bb0115 article-title: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome publication-title: J Thromb Haemost – volume: 5 start-page: 325 year: 2009 end-page: 329 ident: bb0120 article-title: Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? publication-title: EuroIntervention – volume: 117 start-page: 5189 year: 2011 end-page: 5197 ident: bb0125 article-title: Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity publication-title: Blood – volume: 5 start-page: 1630 year: 2007 end-page: 1636 ident: bb0055 article-title: Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events publication-title: J Thromb Haemost – volume: 4 start-page: 585 year: 2011 end-page: 594 ident: bb0165 article-title: Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin publication-title: Circ Cardiovasc Interv – volume: 60 start-page: 290 year: 2012 end-page: 299 ident: bb0170 article-title: Prospective study on circulating MicroRNAs and risk of myocardial infarction publication-title: J Am Coll Cardiol – volume: 3 start-page: 85 year: 2005 end-page: 92 ident: bb0070 article-title: Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases publication-title: J Thromb Haemost – volume: 33 start-page: 1241 year: 2012 end-page: 1249 ident: bb0050 article-title: High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study publication-title: Eur Heart J – volume: 97 start-page: 983 year: 2011 end-page: 990 ident: bb0015 article-title: High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention publication-title: Heart – volume: 19 start-page: 551 year: 2008 end-page: 554 ident: bb0060 article-title: Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay publication-title: Platelets – volume: 60 start-page: 645 year: 2012 end-page: 681 ident: bb0005 article-title: 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines publication-title: J Am Coll Cardiol – volume: 136 start-page: 215 year: 2009 end-page: 233 ident: bb0095 article-title: MicroRNAs: target recognition and regulatory functions publication-title: Cell – volume: 9 start-page: 1582 year: 2011 end-page: 1589 ident: bb0145 article-title: Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel publication-title: J Thromb Haemost – volume: 5 start-page: 1839 year: 2007 end-page: 1847 ident: bb0150 article-title: Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients publication-title: J Thromb Haemost – volume: 120 start-page: 2337 year: 2009 end-page: 2344 ident: bb0040 article-title: Smoking, clopidogrel, and mortality in patients with established cardiovascular disease publication-title: Circulation – volume: 16 start-page: 961 year: 2009 end-page: 966 ident: bb0100 article-title: Existence of a microRNA pathway in anucleate platelets publication-title: Nat Struct Mol Biol – volume: 118 start-page: 2960 year: 2011 end-page: 2969 ident: bb0175 article-title: MicroRNA function in myeloid biology publication-title: Blood – volume: 116 start-page: 281 year: 2004 end-page: 297 ident: bb0080 article-title: MicroRNAs: genomics, biogenesis, mechanism, and function publication-title: Cell – volume: 360 start-page: 354 year: 2009 end-page: 362 ident: bb0020 article-title: Cytochrome p-450 polymorphisms and response to clopidogrel publication-title: N Engl J Med – volume: 117 start-page: 2395 year: 2008 end-page: 2399 ident: bb0135 article-title: Logistic regression publication-title: Circulation – volume: 160 start-page: 543 year: 2010 end-page: 551 ident: bb0010 article-title: Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis publication-title: Am Heart J – volume: 302 start-page: 849 year: 2009 end-page: 857 ident: bb0025 article-title: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy publication-title: JAMA – volume: 99 start-page: 112 year: 2010 end-page: 122 ident: bb0140 article-title: De novo protein synthesis in mature platelets: a consideration for transfusion medicine publication-title: Vox Sang – volume: 8 start-page: 369 year: 2010 end-page: 378 ident: bb0105 article-title: VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA publication-title: J Thromb Haemost – volume: 79 start-page: 351 year: 2010 end-page: 379 ident: bb0090 article-title: Regulation of mRNA translation and stability by microRNAs publication-title: Annu Rev Biochem – volume: 52 start-page: 1557 year: 2008 end-page: 1563 ident: bb0030 article-title: Calcium-channel blockers reduce the antiplatelet effect of clopidogrel publication-title: J Am Coll Cardiol – volume: 466 start-page: 835 year: 2010 end-page: 840 ident: bb0085 article-title: Mammalian microRNAs predominantly act to decrease target mRNA levels publication-title: Nature – volume: 1 start-page: 219 year: 2005 end-page: 227 ident: bb0130 article-title: The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease publication-title: EuroIntervention – volume: 98 start-page: 139 year: 2012 end-page: 144 ident: bb0160 article-title: Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents publication-title: Heart – volume: 4 start-page: 365 year: 2011 end-page: 380 ident: bb0035 article-title: Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations publication-title: JACC Cardiovasc Interv – volume: 19 start-page: 493 year: 2003 ident: 10.1016/j.thromres.2013.02.015_bb0155 article-title: SNARE protein structure and function publication-title: Annu Rev Cell Dev Biol doi: 10.1146/annurev.cellbio.19.110701.155609 – volume: 16 start-page: 961 year: 2009 ident: 10.1016/j.thromres.2013.02.015_bb0100 article-title: Existence of a microRNA pathway in anucleate platelets publication-title: Nat Struct Mol Biol doi: 10.1038/nsmb.1651 – volume: 117 start-page: 5189 year: 2011 ident: 10.1016/j.thromres.2013.02.015_bb0125 article-title: Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity publication-title: Blood doi: 10.1182/blood-2010-09-299719 – volume: 118 start-page: 2960 year: 2011 ident: 10.1016/j.thromres.2013.02.015_bb0175 article-title: MicroRNA function in myeloid biology publication-title: Blood doi: 10.1182/blood-2011-03-291971 – volume: 1 start-page: 219 year: 2005 ident: 10.1016/j.thromres.2013.02.015_bb0130 article-title: The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease publication-title: EuroIntervention – volume: 120 start-page: 2337 year: 2009 ident: 10.1016/j.thromres.2013.02.015_bb0040 article-title: Smoking, clopidogrel, and mortality in patients with established cardiovascular disease publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.109.866533 – volume: 4 start-page: 365 year: 2011 ident: 10.1016/j.thromres.2013.02.015_bb0035 article-title: Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations publication-title: JACC Cardiovasc Interv doi: 10.1016/j.jcin.2010.12.009 – volume: 19 start-page: 551 year: 2008 ident: 10.1016/j.thromres.2013.02.015_bb0060 article-title: Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay publication-title: Platelets doi: 10.1080/09537100802272634 – volume: 9 start-page: 1582 year: 2011 ident: 10.1016/j.thromres.2013.02.015_bb0145 article-title: Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2011.04414.x – volume: 117 start-page: 2395 year: 2008 ident: 10.1016/j.thromres.2013.02.015_bb0135 article-title: Logistic regression publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.682658 – volume: 33 start-page: 1241 year: 2012 ident: 10.1016/j.thromres.2013.02.015_bb0050 article-title: High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study publication-title: Eur Heart J doi: 10.1093/eurheartj/ehr407 – volume: 5 start-page: 1839 year: 2007 ident: 10.1016/j.thromres.2013.02.015_bb0150 article-title: Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2007.02656.x – volume: 136 start-page: 215 year: 2009 ident: 10.1016/j.thromres.2013.02.015_bb0095 article-title: MicroRNAs: target recognition and regulatory functions publication-title: Cell doi: 10.1016/j.cell.2009.01.002 – volume: 8 start-page: 369 year: 2010 ident: 10.1016/j.thromres.2013.02.015_bb0105 article-title: VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2009.03700.x – volume: 98 start-page: 139 year: 2012 ident: 10.1016/j.thromres.2013.02.015_bb0160 article-title: Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents publication-title: Heart doi: 10.1136/hrt.2011.227272 – volume: 5 start-page: 1630 year: 2007 ident: 10.1016/j.thromres.2013.02.015_bb0055 article-title: Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2007.02609.x – volume: 32 start-page: 2999 year: 2011 ident: 10.1016/j.thromres.2013.02.015_bb0110 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehr236 – volume: 60 start-page: 290 year: 2012 ident: 10.1016/j.thromres.2013.02.015_bb0170 article-title: Prospective study on circulating MicroRNAs and risk of myocardial infarction publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2012.03.056 – volume: 97 start-page: 983 year: 2011 ident: 10.1016/j.thromres.2013.02.015_bb0015 article-title: High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention publication-title: Heart doi: 10.1136/hrt.2010.220491 – volume: 79 start-page: 351 year: 2010 ident: 10.1016/j.thromres.2013.02.015_bb0090 article-title: Regulation of mRNA translation and stability by microRNAs publication-title: Annu Rev Biochem doi: 10.1146/annurev-biochem-060308-103103 – volume: 4 start-page: 585 year: 2011 ident: 10.1016/j.thromres.2013.02.015_bb0165 article-title: Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin publication-title: Circ Cardiovasc Interv doi: 10.1161/CIRCINTERVENTIONS.111.962555 – volume: 4 start-page: 542 year: 2006 ident: 10.1016/j.thromres.2013.02.015_bb0115 article-title: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2005.01751.x – volume: 160 start-page: 543 year: 2010 ident: 10.1016/j.thromres.2013.02.015_bb0010 article-title: Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis publication-title: Am Heart J doi: 10.1016/j.ahj.2010.06.004 – volume: 52 start-page: 1557 year: 2008 ident: 10.1016/j.thromres.2013.02.015_bb0030 article-title: Calcium-channel blockers reduce the antiplatelet effect of clopidogrel publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2008.07.055 – volume: 466 start-page: 835 year: 2010 ident: 10.1016/j.thromres.2013.02.015_bb0085 article-title: Mammalian microRNAs predominantly act to decrease target mRNA levels publication-title: Nature doi: 10.1038/nature09267 – volume: 3 start-page: 85 year: 2005 ident: 10.1016/j.thromres.2013.02.015_bb0070 article-title: Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2004.01063.x – volume: 98 start-page: 1329 year: 2007 ident: 10.1016/j.thromres.2013.02.015_bb0075 article-title: The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis publication-title: Thromb Haemost doi: 10.1160/TH07-05-0324 – volume: 116 start-page: 281 year: 2004 ident: 10.1016/j.thromres.2013.02.015_bb0080 article-title: MicroRNAs: genomics, biogenesis, mechanism, and function publication-title: Cell doi: 10.1016/S0092-8674(04)00045-5 – volume: 99 start-page: 112 year: 2010 ident: 10.1016/j.thromres.2013.02.015_bb0140 article-title: De novo protein synthesis in mature platelets: a consideration for transfusion medicine publication-title: Vox Sang doi: 10.1111/j.1423-0410.2010.01333.x – volume: 52 start-page: 1052 year: 2008 ident: 10.1016/j.thromres.2013.02.015_bb0045 article-title: Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2008.05.054 – volume: 360 start-page: 354 year: 2009 ident: 10.1016/j.thromres.2013.02.015_bb0020 article-title: Cytochrome p-450 polymorphisms and response to clopidogrel publication-title: N Engl J Med doi: 10.1056/NEJMoa0809171 – volume: 157 start-page: e561 issue: 562 year: 2009 ident: 10.1016/j.thromres.2013.02.015_bb0065 article-title: Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin publication-title: Am Heart J – volume: 5 start-page: 325 year: 2009 ident: 10.1016/j.thromres.2013.02.015_bb0120 article-title: Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? publication-title: EuroIntervention doi: 10.4244/51 – volume: 302 start-page: 849 year: 2009 ident: 10.1016/j.thromres.2013.02.015_bb0025 article-title: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy publication-title: JAMA doi: 10.1001/jama.2009.1232 – volume: 60 start-page: 645 year: 2012 ident: 10.1016/j.thromres.2013.02.015_bb0005 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2012.06.004 – reference: 23597855 - Thromb Res. 2013 Jun;131(6):472-3 |
SSID | ssj0017195 |
Score | 2.3854492 |
Snippet | We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary... Abstract Objectives We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 508 |
SubjectTerms | Aged Blood Platelets - drug effects Blood Platelets - metabolism Clopidogrel Coronary Disease - drug therapy Coronary Disease - genetics Down-Regulation - drug effects Female Hematology, Oncology and Palliative Medicine High on-treatment platelet reactivity Humans Male MicroRNAs - genetics Middle Aged MiroRNAs Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Platelet function test Platelet Function Tests Ticlopidine - analogs & derivatives Ticlopidine - pharmacology Ticlopidine - therapeutic use Vasodilator-stimulated phosphoprotein |
Title | Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0049384813000820 https://www.clinicalkey.es/playcontent/1-s2.0-S0049384813000820 https://dx.doi.org/10.1016/j.thromres.2013.02.015 https://www.ncbi.nlm.nih.gov/pubmed/23498169 https://www.proquest.com/docview/1366822311 |
Volume | 131 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dSxwxEB9EQXwptdr22ioR-hov2U2ym0exlWuLPkgF3-LmY-Hk3Du6J_TJv93Jbvaq2FJpX0M-lpnJzG828wHw0TvmfGkZtbUsqbBaUbRymnorM1W52kodE4VPz9TkQny9lJdrcDzkwsSwyqT7e53eaes0Mk7UHC-m05jjK3Qeq8HnvSGLGeyiiFJ-eLcK8-AF130XA6FpnP0gS_j6MLYiuEG3NoZ45V3tztge9_cG6k8AtDNEJy_hRUKQ5Kj_yG1YC80r2DxNb-Q7cPWpQ4Jt8GQxQySJjCE303OKFpqEnynutSHTllSJNTgz_o4lsXQxmTfUxSwqP0dPfPZrC9zS9Z0mduHi5PP34wlNfRSoE0W5pBqvmfSS2QJtdZ4Fz0WNngdzSJNaFplzBQ6pigcrVeAWPbRKeeYE8hHxX52_hvVm3oS3QALjQQjhEVgg9GC-lDhNh9IXvHZWlSOQA_GMS0XGY6-LmRmiya7NQHQTiW5YZpDoIxiv1i36Mht_XVEMvDFDEimqPYOW4N9Whjbd3tZw0-JM80TCRqBXKx8J6bNOPRgEyOANjs8yVRPmt3harhTCtJzzEbzpJWtFgywXuuRKv_uPk9_DVtb38KCMf4D15Y_bsIdIamn3u6uyDxtHX75Nzu4BZsIeJQ |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-NTgJeEOOzMMCT9mpqJ7YTP04bU_fRPqBN2puJPyJ16tKKdBJ_PufGKSA2geDV8tnRne_ud7HvDmDfO-Z8aRm1tSypsFpR9HKaeiszVbnaSh0ThSdTNb4Up1fyagsO-1yY-Kwy2f7Opq-tdRoZJW6OlrNZzPEVOo_V4PPOkT2A7VidSg5g--DkbDzdXCYUXHeNDISmkeCnROHrj7EbwQ1GtvGVV74u3xk75N7to-7DoGtfdPwUniQQSQ6679yBrdA8g4eTdE3-HL4crcFgGzxZzhFMomzIzewzRSdNwrf09LUhs5ZUSTo4M_6RJbF6MVk01MVEKr_AYHz-Ywlc0nXNJl7A5fGni8MxTa0UqBNFuaIaNU16yWyB7jrPgueixuCDOeRJLYvMuQKHVMWDlSpwi0FapTxzAkWJELDOX8KgWTThNZDAeBBCeMQWiD6YLyVO06H0Ba-dVeUQZM8841Kd8djuYm76B2XXpme6iUw3LDPI9CGMNnTLrtLGHymKXjamzyNFy2fQGfwbZWiTAreGmxZnmt8O2RD0hvKXc_pXu-71B8igEsebmaoJi1vcLVcKkVrO-RBedSdrw4MsF7rkSr_5j50_wKPxxeTcnJ9Mz97C46xr6UEZ34XB6utteIfAamXfJ8X5DiHdINY |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decreased+platelet+miR-223+expression+is+associated+with+high+on-clopidogrel+platelet+reactivity&rft.jtitle=Thrombosis+research&rft.au=Shi%2C+Rui&rft.au=Ge%2C+Lan&rft.au=Zhou%2C+Xin&rft.au=Ji%2C+Wen-Jie&rft.date=2013-06-01&rft.issn=0049-3848&rft.volume=131&rft.issue=6&rft.spage=508&rft.epage=513&rft_id=info:doi/10.1016%2Fj.thromres.2013.02.015&rft.externalDBID=ECK1-s2.0-S0049384813000820&rft.externalDocID=1_s2_0_S0049384813000820 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00493848%2FS0049384813X00088%2Fcov150h.gif |